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Figure 3. Mean arterial pressure over time of Flox mice (A) and cKO mice
(B). The hypertensive effects of pazopanib are more evident in cKO mice (B,
red line) at week 2 compared to Flox control mice (A, red line). Lisinopril co-
treatment was more effective at attenuating the hypertensive effects of
pazopanib in cKO mice (B, blue line) compared to flox control mice (A, blue
line).
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Electrophysiology results in WT cardiomyocytes after 
42-day treatment
Most patients with cancer now die from cardiovascular
(CV) disease rather than from cancer itself and nearly
half of patients with renal cell carcinoma experience
CV side-effects from the gold-standard therapy—
pazopanib1-3. Pazopanib is a tyrosine kinase inhibitor
(TKI) that inhibits vascular endothelial growth factor
receptors (VEGFRs). The clinical use of pazopanib
and other TKIs is strongly limited by their association
with serious CV side effects. Although little is known
about its mechanism, pazopanib causes serious CV
effects in 50% of treated patients, including
hypertension (HTN), heart failure (HF) and myocardial
ischemia1-3. It is imperative to explore the mechanisms
by which this life-saving drug induces HTN and HF in
order to develop strategies to mitigate CV insult and
sustain cancer treatment for as long as possible.
We have created a structural heart disease model in
mice which display early signs of HF similar to
humans. These mice (cKO mice) lack cardiac βII-
spectrin, a cytoskeletal protein. These mice have
arrhythmias, spontaneous Ca2+ release and abnormal
expression/localization of cardiac membrane
proteins4. Our previous microarray data shows that
fibroblast growth factor-2 transcript levels are reduced
by >50% in cKO mice.
Additionally, wild type (WT) mice with induced HF and
humans with HF or atrial fibrillation show
downregulation of βII-spectrin in the heart.
We hypothesize that the hypertensive effects of
pazopanib are due to sustained activation of the renin-
angiotensin-aldosterone system (RAAS), which may
be mitigated by Lisinopril. Furthermore, we
hypothesize that mortality will be increased in cKO
mice due to baseline deficiency in angiogenic
pathways.
These results support the involvement of the RAAS pathway in the
hypertensive effects of pazopanib. We plan to repeat this experiment
in order to obtain sufficient n values for power. Echocardiography and
electrocardiography will be used to asses structural changes in the
myocardium as a result of pazopanib treatment. Electrophysiology
studies will be performed on cardiomyocytes from mice after 22-days
of treatment. Western blotting and microarray analysis will be used to
determine which genes are affected by pazopanib treatment.
Our overall goal is to confirm the involvement of the RAAS pathway
in the hypertensive effects of pazopanib and the efficacy of Lisinopril
co-treatment. Furthermore, we hope to determine whether pazopanib
is directly toxic to cardiomyocytes or the vascular endothelium, and
whether the cardioprotective properties of Lisinopril are dependent
upon its hypotensive effect.
With regards to βII-spectrin, we hope to demonstrate the role of this
protein in angiogenic and growth factor pathways, and whether this
protein has efficacy as a HF biomarker. Urine and blood samples
from mice treated with pazopanib will be analyzed for βII-spectrin
breakdown products by western blotting and mass spectrometry.
Mice
8-Week-old black male WT mice were orally dosed with 30 mg/kg
of pazopanib twice daily for 42 days. WT mice and cKO mice
were orally dosed with 100 mg/kg of pazopanib and/or 20 mg/kg
of Lisinopril once daily for 22 days; flox mice were used as
controls.
Blood Pressure
The CODA system was used to gather non-invasive blood
pressure readings once per week.
Electrophysiology
Ventricular cardiomyocytes were isolated from mice by
Langendorff preparation and tested in vitro.
Mouse Measurements
Heart weight and tibia length were measured immediately after
organ removal at the conclusion of the experiment.
Immunoblots
Mouse whole heart lysates were electrophoresed and tested with
anti-VEGFR-2 antibody.
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Figure 1. Mean arterial pressure over time of control group
(black) compared to mice treated with pazopanib (red). A two-way
ANOVA showed a significant increase (p<0.05) in mean arterial
pressure due to drug treatment but not due to time (n=7). * indicates
statistical significance. Error bars represent + standard error of mean.
Hz/TREATMENT APD50 +/- SE APD75 +/- SE APD90 +/- SE
0.5 WT 2.08 +/- 0.13 5.29 +/- 0.63 12.20 +/- 2.22
0.5 DRUG 3.33 +/- 0.60 8.26 +/- 1.32 16.14 +/- 2.12
1.0 WT 1.92 +/- 0.15 4.77 +/- 0.58 10.11 +/- 1.31
1.0 DRUG 3.13 +/- 0.58 7.74 +/- 1.27 15.20 +/- 1.96
change due to drug: p=0.007*
change due to time: not significant
change due to drug over time: p=0.034*
Mean arterial blood pressure over 42-day treatment
Figure 2. Pazopanib treatment causes precursors to arrhythmias.
Average action potential duration (APD) 50, 75 and 90 of myocytes
from treated mice (red) was significantly elevated compared to control
myocytes (black). 2/6 myocytes from treated mice developed delayed
afterdepolarizations (DADs) while these were not observed in 5
control myocytes (n=2).
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Mean arterial blood pressure over 22-day treatment
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Survival rate over 22-day treatment 
Figure 4. Pazopanib treatment is associated with increased mortality. WT
and transgenic mouse groups dosed with 100 mg/kg of pazopanib for 22 days
(red) had increased mortality compared to control mice (green). Lisinopril
cotreatment decreased mortality in Flox mice only (blue). n=3 WT DMSO; n=3 WT
Pazopanib/DMSO; n=8 Flox DMSO; n=3 Flox Pazopanib/DMSO; n=7 Flox DMSO + Lisinopril;
n=3 Flox Pazopanib/DMSO + Lisinopril; n=6 KO DMSO; n=5 KO Pazopanib/DMSO; n=5 KO
DMSO + Lisinopril; n=4 Pazopanib/DMSO + Lisinopril.
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Heart weight measurements after 22-day treatment
Figure 5. Heart weight-tibia length ratio at conclusion of 22-day
treatment. Pazopanib (red) was associated with increased heart
weight at the conclusion of treatment compared to control mice
(green). Heart weight measurements have yet to be obtained from
Flox mice treated with pazopanib.
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